Altesa Biosciences Secures $75 Million Series B Following Positive Phase 2a Rhinovirus Challenge Study in COPD

by Virtus | Feb 27, 2026

  Virtus Respiratory Research Ltd is pleased to share that our collaboration with AltesaBiosciences, Inc. has contributed to the successful close of a $75 million oversubscribedSeries B financing.The financing follows positive results from a Phase 2a human...

Vapendavir for rhinovirus-triggered COPD exacerbations: phase 2a study results

by Virtus | Oct 16, 2025

Click the button below to read more about...

Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

by Virtus | Jul 2, 2025

LONDON – VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa...

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

by Virtus | Dec 6, 2019

Click the button below to read more about this. CLICK HERE FOR ARTICLE  ...

Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

by Virtus | Dec 6, 2019

Click the button below to read more about this. CLICK HERE FOR...